A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- 02 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Nov 2017.
- 02 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2017.
- 17 May 2016 Status changed from not yet recruiting to recruiting.